Monoamine oxidase B (MAOB) is an enzyme involved in the metabolism of dopamine. It converts dopamine to its corresponding carboxylic acid via an aldehyde intermediate. MAOB regulates both the free intraneuronal concentration of dopamine and the releasable stores. MAOB inhibitors bind to and inhibit MAOB, preventing dopamine degradation. This results in greater stores of dopamine available for release. MAOB inhibitors are used in the treatment of depression. People with depression have higher levels of the brain protein MAOB than people without depression.
Click here: Learn about the role of MAO-B inhibitors in depression treatment
Related content
One hypothesis of the cycle of anhedonia (loss of interest or pleasure) in patients with depression is illustrated in this image; this hypothesis comes from a series of experiments performed on a sample of psychology students.
As adjunctive treatment in MDD, some dopamine–serotonin receptor antagonists are associated with sedating side effects, while others are more often associated with ‘activating’ side effects.